Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous CSL730 in Healthy Adults
NCT04446000Phase 1Terminated
- Sponsor
- CSL Limited
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CSL730 (11 arms), sponsored by CSL Limited. Primary endpoints: Treatment Emergent Adverse Events at 56 days, Percent of subjects with TEAEs at 56 days and 2 more. Started Sep 2020; status: terminated.
02
Drugs
CSL730
Beyond the preview
Go deeper on NCT04446000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446000.